Industry Trend Analysis - Pharmaceutical Trade - Botswana - Q1 2018 - FEB 2018

BMI View: Multinational drugmaker presence in Botswana will be limited to imports via leading distributors , namely Medswana and Delta. Domestic manufacturing output will increase over the long term and will , given the huge demand, be mainly focussed on generic anti-retrovirals. As such, we maintain our view that Botswana will continue to rely on importing its pharmaceutical needs for the foreseeable future.

Structural Trends

There is a limited drug manufacturing scene in Botswana, reflected in the country's small pharmaceutical market size. As it stands, there is just one other manufacturer and exporter of medication in Botswana - Botswana Vaccine Institute (BWI). Despite domestic company Gemi Pharmacure announcing plans to set up local manufacturing facilities, these are yet to materialise and we expect Botswana's future import reliance to reflect this.

Pharmaceutical Trade Forecast
e/f = BMI estimate/forecast. Source: United Nations Comtrade Database DESA/UNSD, BMI

This article is part of our Middle East & Africa coverage. To access this article subscribe now or sign up for free trial